DAFTAR PUSTAKA

1. Soegondo S. Diagnosis dan Kalsifikasi Diabetes Mellitus Terkini. Dalam

Soegondo S dkk (eds), Penatalaksanaan Diabetes Mellitus Terpadu.
Penerbit FKUI. Jakarta. 2005.
2. Suyono S. Patofisiologi Diabetes Mellitus. Dalam Soegondo S dkk (eds),
Penatalaksanaan Diabetes Mellitus Terpadu. Penerbit FKUI. Jakarta.
2005.
3. Koenig W, Khuseyinova N, Baumert J, et al. Serum Concentrations of
Adiponectin and Risk of Type 2 Diabetes Mellitus and Coronary Heart
Disease in Apparently Healthy Middle-Aged Men : Results From the 18
year follow up of a Large Cohort From Southern Germany. Journal of
American College of Cardiology 2006; 48:1369-77.
4. Haffner SM, Lehto S, Ronneemaa T, Pyorala K, Laakso M. Mortality from
coronary heart disease in subjects with Type 2 diabetes and in nondiabetic
subjects with and without prior myocardial infarction. N Engl J Med. 1998 ;
339; 229-34.
5. Shahab A. Komplikasi Kronik DM Penyakit Jantung Koroner. Dalam
Sudoyo AW, dkk (eds), Buku Ajar Ilmu Penyakit Dalam jilid III, edisi IV.
Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI, Jakarta, 2009.
Universitas Sumatera Utara
6. Sharpless JL. Polycystic Ovary Syndrome and the Metabolic Syndrome.
Clinical Diabetes 2003;21:154-7.
7. Fard A, Tuck CH, Donis JA, et al. Acute Elevations of Plasma Asymmetric
Dimethylarginine and Impaired Diabetes Endothelial Function in Response
to a High-Fat Meal in Patients with Type 2. Arterioscler Thromb Vasc
Biol.2000; 20; 2039-44.
8. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia
attenuates endothelium-dependent vasodilation in humans in vivo.
Circulation.1998; 97:1695-1701.
9. Soewondo P. Pemantauan Pengendalian Diabetes Mellitus. Dalam
Soegondo S dkk (eds), Penatalaksanaan Diabetes Mellitus Terpadu.
Penerbit FKUI. Jakarta. 2005.
10. Aqil S, Jaleel A, Jaleel F, Basir F. Comparison of Adiponectin in Ischemic
Heart Disease Versus Ischemic Stroke in Diabetic Patients. World Applied
Science journal 2008; 3: 759-62.
11. Stejskal D, Ruzieka V, Adamovska S, et al. Adiponectin Concentration as
a Criterion of Metabolic Control in Persons with type 2 Diabetes Mellitus?.
Biomed Papers 2003;147(2):167-72.
12. Duncan BB, Schmidt MI, Pankow JS, et al. Adiponectin and the
Development of Type 2 Diabetes, The Atherosclerosis Risk in
Communities Study.Diabetes 2004; 53: 2473-78.
13. Scherer PE. Adipose Tissue, From Lipid Storage Compartment to
Endocrine Organ. Diabetes 2005; 55: 1537-45.
Universitas Sumatera Utara
14. Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines : Molecular
Links between Obesity and Atherosclerosis. Am J Physiol Heart Circ
Physiol 2005; 288 : H2031-H2041.
15. Ouchi NS, Kihara Y, Arita K, Maeda H, Kuriyama Y, Okamoto K, et al.
Novel Modulator for Endothelial Adhesion Molecules : Adipocyte-derived
plasma protein, adiponectin. Circulation. 1999; 100; 2473-2476.
16. Daimon M, Oizumi T, Saitoh T, et al. Decreased Serum Levels of
Adiponectin are a Risk Factor for the Progression to Type 2 Diabetes in
the Japanese Population. Diabetes Care 2003;26:2015-20
17. Nakashima R, Kamei N, Yamane K, et al. Decrease Total and High
Molecular Weight Adiponectin are Independent Risk Factors for the
Development o0f Type 2 Diabetes in Japanese Americans. J Clin
Endocrinol Metab 2006;91:3873-7
18. Hotta K, Funahashi T, Arita Y, et al. Plasma Concentrations of a Novel,
Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients.
Arterioscler Thromb Vasc Biol 2000;20:1595-9.
19. Sungkar MA. Hubungan Antara Pengendalian Metabolik dan Komplikasi
Kronik Diabetes Tipe 2 pada Penyakit Kardiovaskular. Dalam Darmono,
dkk (eds), Naskah Lengkap Diabetes Mellitus Ditinjau dari Berbagai Aspek
Penyakit Dalam. Badan Penerbit Universitas Diponegoro. Semarang.
2007. 257-65.
20. Gallagher EJ, Roith D, Bloomgarden Z. Review of hemoglobin A1C in the
management of diabetes. Journal of diabetes 2009 ; 1 : 9-17.
Universitas Sumatera Utara
21. Konsensus Pengelolaan dan Pencegahan Diabetes Mellitus Tipe 2 di
Indonesia 2006. PB PERKENI. Jakarta. 2006.
22. Report of the expert committee on the diagnosis and classification of
diabetes mellitus. Diabetes Care. 2003; 26 Suppl 1: S5-20.
23. Pischon T, Rimm EB. Adiponectin : A Promising Marker for Cardiovascular
Disease. Clin Chem 2006 ; 52 : 797-799.
24. Meier U, Gressner M. Endocrine Regulation of Energi Metabolism :
Review of Pathobiochemical and Clinical Chemical Aspects of Leptin,
Ghrelin, Adipnectin, and Resistin. Clin Chem 2004; 50: 1511-1525.
25. Xu Dan-yan, Zhao Shui-Ping, Huang Qiu-xia, Du wei, Liu Yu-hua, Liu Ling,
Xie Xiao-mei. Effects of Glimepiride on metabolic parameters and
cardiovascular risk factors in patients with newly diagnosed type 2
diabetes mellitus. Diabetes Research and Clinical Practice. 2010; 88 : 71-
75.
26. Pscherer S, Heemann U, Frank H. Effect of Renin-Angiotensin System
Blockade on Insulin Resistance and Inflammatory Parameters in Patients
with Impaired Glucose Tolerance. Diabetes Care. 2010; 33 : 914-919.
27. Matsubara M. Plasma Adiponectin Decrease in Women with Nonalcoholic
Fatty Liver. Endocrine Journal 2004;51:587-93
28. Goldstein BJ, Scalia R. Adiponectin: A Novel Adipokine Linking
Adipocytes and Vaskuler Funtion. J Clin Endocrinol Metab 2004;
89(6):2563-8
Universitas Sumatera Utara
29. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and
Metabolic Syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.
30. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-Derived Plasma Protein
Adiponectin Acts as a Platelet-Derived Growth Factor-BB-Binding Protein
and Regulates Growth Factor-Induced Common Post Receptor Signal in
Vaskuler Smooth Muscle Cell. Circulation 2002;105:2893-8.
31. Ouchi N, Kihara S, Anita Y. Adiponectin, an Adipocyte-Derived Plasma
Protein, Inhibits Endothelial NF-
k
B Signaling a cAMP-Dependent Pathway.
Circulation 2000;102:1296-301
32. Ouchi N, Kihara S, Anita Y, et al. Novel Modulator for Endothelial
Adhesion Molecules. Circulation 1999;100:2473-6
33. Kadowaki T, Yamauchi T. Adiponectin and Adiponectin Receptors.
Endocrine Reviews 2005;26:439-51
34. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses
proliferation and super oxide generation and enhances eNOS activity in
endothelial cells treated with oxidized LDL. Biochem Biophys Res
Commun 2004;315:264-271.
35. Bennet CM, Guo M, Dharmage SC. HbA1C as a screening tool for
detection of type 2 diabetes : a systematic review. Diabetic Medicine 2007;
24 : 333-343.
36. Buell C, Kermah D, Davidson. Utility of A1C for diabetes screening in the
1999-2004 NHANES Population. Diabetes Care 2007; 30 : 2233-2235
Universitas Sumatera Utara
37. Selvin E, Steffes MW, Matshushita K, Wagenknecht L, Pankow J, Coresh
J, Brancati FL. Glycated Hemoglobin, Diabetes, and Cardiovascular risk in
nondiabetic adults. N Engl J Med 2010; 362 : 800-811.
38. Little RR, Sacks DB. HbA1C : how do we measure it and what does it
mean? Curr Opin Endocrinol Diabetes Obes 2009; 16 : 113-118.
39. Kramer CK, Araneta MR, Barret-Connor E. A1C and diabetes diagnosis :
the rancho bernardo study. Diabetes Care 2010; 33 : 101-103.
40. Bruns DE, Boyd JC. Few point of care hemoglobin A1C assay methods
meet clinical needs. Clinical Chemistry 2010; 56 (1) : 4-6.
41. Yunir E, Soebardi S. Terapi non farmakologis pada diabetes mellitus.
Dalam Sudoyo AW, dkk (eds), Buku Ajar Ilmu Penyakit Dalam jilid III, edisi
IV. Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI, Jakarta,
2009.
42. Waspadji S. Diabetes Mellitus : Mekanisme dasar dan pengelolaannya
yang rasional. Dalam Soegondo S dkk (eds), Penatalaksanaan Diabetes
Mellitus Terpadu. Penerbit FKUI. Jakarta. 2005.
43. Wagner JA, Wright EC, Ennis MM, Prince M, Kochan J, Nunez DJR, et al.
Utility of Adiponectine as a Biomarker Predictive of Glycemic Efficacy is
Demonstrated by Collaborative Pooling of Data From Clinical Trials
Conducted by Multiple Sponsors. Clinical Pharmacology and
Theraupetics. 2009.
Universitas Sumatera Utara
44. Fahranak Z, Djalil M, Hosseinzadeh MJ, Eshragheian MR. Comparing
Serum Leptin and Adiponectin Levels in Controlled and Non-controlled
type 2 Diabetes. ARYA Atherosclerosis Journal 2007; 3; 135-138.
45. Krakoff J, Funahashi T, Stehouwer CDA, Schalwijk CG, Tanaka S,
Matsuzawa Y. Inflammatory markers, adiponectin, and risk of type 2
diabetes in the Pima Indian. Diabetes Care; 26; 6 : 1745-1751.
46. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma
adiponectin levels and risk of myocardial infarction in men. JAMA, 2004;
291, 14; 1730-1737.
47. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. Relationship between
adiponectin and glycemic control, blood lipids, and inflammatory markers
in men with type 2 diabetes. Diabetes Care 2004; 27; 1680-1687.
48. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani
H, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing
adipocyte-derived protein. Diabetes, 2002; 51 : 2734-2741.
49. Kim M-J, Yoo K-H, Park H-S, Chung S-M, Jin C-J, Lee Y. Plasma
adiponectin and insulin resistance in Korean type 2 diabetes
mellitus.Yonsei Med J, 2005; 46 : 42-50.
50. Zurawska-Klis M, Kasznicki J, Kosmalski M, Smigielski J, Drzewoski J.
Adiponectin plasma concentration, type 2 diabetes mellitus, cardiovascular
diseases and features of metabolic syndrome. Diabetologia
Doswiadczalna I Kliniczna 2009; 9; 2; 81-87.
Universitas Sumatera Utara
51. Fernandez-Real JM, Botas-Cervero P, Lopez-Bermano A, Casamitjana R,
Funahashi T, Delgado E, et al. Adiponectin is independently associated
with glycosilated haemoglobin. European journal of endocrinology, 2004;
150; 201-205.
52. Tabak AG, Brunner EJ, Miller MA, Karanam S, McTernan PG, Capuccio
FP, et al. Low serum adiponectin predicts 10-year risk of type 2 diabetes
and HbA1C independently of obesity, lipids and inflammation-Whitehall II
study. Horm Metab Res, 2009; 41 (8); 626-629.
53. Manucci E, Ognibene A, Crenasco F, et al. Plasma adiponectin and
hyperglycaemia in diabetic patients. Clin Chem Lab Med 2003; 41 : 1131-
1135.






















Universitas Sumatera Utara